Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.
The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University.
The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | -0.56 Increased by +9.68% | -0.69 Increased by +18.84% |
| Mar 5, 24 | -0.83 Decreased by -48.21% | -0.74 Decreased by -12.16% |
| Nov 2, 23 | -0.81 Decreased by -42.11% | -0.68 Decreased by -19.12% |
| Aug 8, 23 | -0.65 Decreased by -10.17% | -0.67 Increased by +2.99% |
| May 4, 23 | -0.62 Decreased by -26.53% | -0.63 Increased by +1.59% |
| Feb 28, 23 | -0.56 Decreased by -30.23% | -0.59 Increased by +5.08% |
| Nov 9, 22 | -0.57 Decreased by -26.67% | -0.58 Increased by +1.72% |
| Aug 8, 22 | -0.59 Decreased by -73.53% | -0.51 Decreased by -15.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.52 M Increased by +272.73% | -38.26 M Decreased by -53.29% | Decreased by -2.52 K% Increased by +58.87% |
| Jun 30, 23 | 268.00 K Increased by +64.42% | -30.50 M Increased by +41.98% | Decreased by -11.38 K% Increased by +64.71% |
| Mar 31, 23 | 967.00 K Increased by +455.75% | -22.41 M Decreased by -3.95% | Decreased by -2.32 K% Increased by +81.30% |
| Dec 31, 22 | 1.61 M Increased by +384.38% | -23.69 M Decreased by -17.58% | Decreased by -1.47 K% Increased by +75.72% |
| Sep 30, 22 | 407.00 K Increased by +166.01% | -24.96 M Decreased by -22.04% | Decreased by -6.13 K% Increased by +54.12% |
| Jun 30, 22 | 163.00 K Decreased by -95.32% | -52.57 M Decreased by -293.09% | Decreased by -32.25 K% Decreased by -8.29 K% |
| Mar 31, 22 | 174.00 K Decreased by -74.60% | -21.56 M Decreased by -30.39% | Decreased by -12.39 K% Decreased by -413.32% |
| Dec 31, 21 | 333.00 K Decreased by -91.20% | -20.15 M Increased by +8.00% | Decreased by -6.05 K% Decreased by -945.98% |